Key Points Animal studies suggest that endogenous, central glucagon-like peptide 1 (GLP-1) regulates both short-term and long-term energy balance, potentially via activation of hindbrain and hypothalamic GLP-1 receptors (GLP1R), respectively Endogenous peripheral GLP-1 may limit meal size by activation of GLP1R on local vagal afferent nerves and stimulation of a gutbrain feedback loop Increasing GLP1R activity by administering GLP-1 receptor agonists reduces food intake and promotes weight loss in humans, but the extent to which endogenous GLP-1 regulates energy balance in humans remains unknown Although diabetes mellitus and obesity appear to be associated with altered GLP-1 system activity, GLP1R agonists retain their efficacy in these contexts, making them a viable therapeutic tool A better understanding of how endogenous central and peripheral GLP-1 regulate energy balance has the potential to maximize our application of GLP-1-based therapies for the treatment of obesity This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access $189.00 per year only $15.75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
For the successful application of ferroptosis in cancer treatment, a more concrete understanding of ferroptosis and cancer is needed
Strenuous exercise has resulted in increases in the inflammatory marker C-reactive protein (CRP) to levels comparable to those seen in cardiovascular disease states 12
Savannah GLP-1 weight loss injections specialists at ProCare Wellness Institute offer medically supervised GLP-1 injections that help reduce appetite, boost metabolism and provide sustainable weight loss for patients in Savannah, Georgia
He said that one of the benefits of Medicaid is that we get to choose, as a state, where we want to make kind of those extra investments or not. He added that covering the medications could be potentially financially feasible for other states
